HAEMATO AG
HAEMATO AG – H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth 40% to EUR 5.93 million, compared to prior year period
DGAP-News: HAEMATO AG / Key word(s): Half Year Results/Dividend Corporate News der HAEMATO AG: H1 2016: Sales growth 40% to EUR 142.27 million, EBIT-growth 40% to EUR 5.93 million, compared to prior year period In the second quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 74.33 million (prior year period: EUR 56.16 million), a growth of 31.9% was achieved. The pleasant sales achievement in the first quarter of EUR 67.94 million was run up by 9.4%. In the first half-year HAEMATO achieved IFRS Group sales of EUR 142.27 million (prior year period: EUR 101.48 million), a growth of 40% was produced. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. HAEMATO AG is listed in the Entry Standard (Open Market) on the Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
2016-08-29 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |